Class summary at a glance.

Every drug in the Calcitonin Gene-related Peptide Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $1.14Bcombined across class
Total Rx claims: 876K242K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ubrogepant

Brand: UBRELVY · 522K Part D claims (CY24) · 154K beneficiaries · First FDA approval: 2019-12-23

Brand-only (no generics) 496 plans require PA

Low NADAC$109.08

→

Avg plan cost$109.15

Part D spend $692.9M 1× spread, current vs floor

Class share

61%

of class CY24 spend

View profile →

Atogepant

Brand: Qulipta · 354K Part D claims (CY24) · 89K beneficiaries · First FDA approval: 2021-09-30

Brand-only (no generics) 612 plans require PA

Low NADAC$38.37

→

Avg plan cost$38.42

Part D spend $448.7M 1× spread, current vs floor

Class share

39%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.